A practice-changing step forward in germ-cell cancer?
Mené sur 263 patients atteints d'une tumeur germinale de pronostic défavorable, cet essai français de phase III évalue, du point de vue de la survie sans progression, l'efficacité d'une chimiothérapie personnalisée basée sur l'évolution de l'expression de marqueurs tumoraux
The objective of treatment for poor-prognosis germ-cell cancer is cure. At present, standard therapy, consisting of four cycles of cisplatin, etoposide, and bleomycin (BEP), achieves this objective in about 50% of patients. In The Lancet Oncology , Karim Fizazi and colleagues 1 present the outcome of an international, phase 3, multicentre, randomised trial in patients with poor-prognosis metastatic germ-cell cancers. The study compared four cycles of BEP with a risk-adapted approach that used early...
The Lancet Oncology , commentaire, 2013